Eric K. Rowinsky, M.D.

Eric K. Rowinsky, M.D. was appointed Navidea’s Chairman of the Board in September 2016, and has served as a director of Navidea since July 2010. He is Executive Chairman and President of Rgenix, Inc., having served since June 2015. He has also been the Head of Research and Development, Executive Vice President, and Chief Medical Officer of Stemline Therapeutics, Inc., from 2012 to 2015, and was the Chief Executive Officer and Founder of Primrose Therapeutics from August 2010 to September 2011, at which time it was acquired by Stemline. From 2005 to December 2009, he served as the Chief Medical Officer and Executive Vice President of Clinical Development and Regulatory Affairs of ImClone Systems Incorporated, a life sciences company which was acquired by Eli Lilly. Prior to that, Dr. Rowinsky held several positions at the Cancer Therapy & Research Center’s Institute of Drug Development, including Director of the Institute, Director of Clinical Research and SBC Endowed Chair for Early Drug Development, and concurrently served as Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio. Dr. Rowinsky was an Associate Professor of Oncology at the Johns Hopkins University School of Medicine, and on active staff at the Johns Hopkins School of Medicine from 1987 to 1996. Dr. Rowinsky is a member of the boards of directors of Biogen Inc., BIND Therapeutics, Inc., and Fortress Biosciences, Inc., publicly-held life sciences companies. He is also an Adjunct Professor of Medicine at New York University. Dr. Rowinsky has extensive research and drug development experience, oncology expertise, corporate strategy and broad scientific and medical knowledge.

Siamon Gordon, MB, ChB, Ph.D.

Siamon Gordon’s research focused on macrophage heterogeneity, differentiation and activation in mice, and later humans, during development, infection and metabolic disease. His interest in cell fusion led to the development of a range of monoclonal antibodies, which have been widely used to study macrophages in tissues such as bone marrow, spleen and the nervous system.

Since 2008, as an Emeritus Professor, he has been immersed in the history of macrophage research — from Ilya Metchnikoff’s pioneering work on the immune system to the discovery of dendritic cells by Ralph Steinman and Zanvil Cohn. The functional significance of macrophage receptors and giant cell formation also remains of interest to him.

Siamon received an honorary doctorate from the University of Cape Town, where he has been involved in the work of the Institute of Infectious Disease and Molecular Medicine for over a decade. During this period he initiated an AIDS prevention project, publishing an educational cartoon booklet. He is an Honorary Member of the American Association of Immunology and a Fellow of the Academy of Medical Science.

Charles Mills, Ph.D.

Dr. Mills is credited with discovering M1 and M2 macrophages and that these immune cells influence inflammation and health in opposing ways. Dr. Mills’ research has fundamentally changed the science of immunology by demonstrating that the innate immune system is the main controlling element in immune responses. Dr. Mills received a Ph.D. in Immunology/Biochemistry from the University of Chicago, and has served on the faculty at Brown University and the University of Minnesota.